Yarrow Bioscience, Inc. (YARW): R&D Expense
$19.24M
Year ended 2025-12-31
$9.84M
Trailing 12 months to 2026-06-30
+1.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.24M | -37.8% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $30.95M | +89.8% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $16.31M | -11.3% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $18.39M | -5.9% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $19.54M | n/c | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $43.53M | -15.0% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $51.20M | -20.6% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $64.47M | n/c | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $29.01M | +157.7% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $11.26M | +285.3% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $2.92M | n/a | 2018-03-28, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $30.25M | -0.6% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
Compare YARW, SLN, ELAB, VCNX side by side · Screen every company in Pharmaceutical Preparations ↗